OGIVRI attaches to HER2* receptors on cells. This may stop the cancer cells from growing and multiplying.

Effective November 29, 2022, Viatris completed the sale of substantially all of its biosimilars portfolio (including related product trademarks) to Biocon Biologics Limited and its subsidiaries (“Biocon”) and the relevant marketing authorizations are in process of being transferred. Viatris Inc. and its subsidiaries (“Viatris”) are not affiliates of Biocon but are providing certain transition services to Biocon following the transaction completion date, such as operating websites (including this site) relating to the biosimilars portfolio on Biocon’s behalf.
Baseline
measurement
Monitor every 3 months in case of significant cardiac dysfunction withhold treatment and monitor every 4 weeks
Monitor every 6 months
(at least for 2 years)
Immediately prior
to starting Ogivri
While receiving
Ogivri treatments
After completing
Ogivri treatments
*Normal cells also have HER2, so HER2 targeted therapies like OGIVRI may also affect healthy cells which may cause serious side effects.